Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ONCT

ONCT - Oncternal Therapeutics Inc Stock Price, Fair Value and News

$0.530.00 (0.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ONCT Price Action

ONCT RSI Chart

ONCT Valuation

ONCT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ONCT Fundamentals

ONCT Revenue

ONCT Earnings

ONCT Profitability

ONCT Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.2M1.8M2.2M0
2023947.0K862.0K659.0K785.0K
20224.3M3.6M1.9M1.5M
20213.5M3.8M5.3M4.3M
20202.5M2.5M2.5M3.4M
20192.8M1.9M2.2M2.4M
201805.4M3.7M4.2M
20125.5M000
201145.5M34.3M23.0M11.7M
2010028.7M42.8M56.8M
200900014.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Oncternal Therapeutics Inc

ONCT
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
 CEO
 WEBSITEoncternal.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES30